Comparison of the efficacy of treatment with clobetasol propionate or bexarotene in early-stage mycosis fungoides.

IF 2.6 4区医学 Q2 DERMATOLOGY

Anais brasileiros de dermatologia Pub Date : 2024-12-30 DOI:10.1016/j.abd.2024.04.011

Aslı Aksu Çerman, Pinar Ozdemir Cetinkaya, Birgül Özkesici Kurt, Artun Kırker, İlknur Altunay

{"title":"Comparison of the efficacy of treatment with clobetasol propionate or bexarotene in early-stage mycosis fungoides.","authors":"Aslı Aksu Çerman, Pinar Ozdemir Cetinkaya, Birgül Özkesici Kurt, Artun Kırker, İlknur Altunay","doi":"10.1016/j.abd.2024.04.011","DOIUrl":null,"url":null,"abstract":"Background: There are few studies in the literature comparing the effectiveness of topical treatments in early-stage mycosis fungoides (MF).Objectives: It was aimed to evaluate the clinical efficacy, side effects and topical treatment compliance with bexarotene or clobetasol propionate in early-stage MF.Methods: A total of 40 patients with stage IA-IB MF were enrolled in the study. Twenty patients were treated with 1% bexarotene gel and 20 patients were treated with 0.05% clobetasol propionate ointment.Results: In the bexarotene group, 11 patients (55%) had complete clinical response (CCR) and 5 patients (25%) had partial response (PR) while in the clobetasol propionate group, 10 patients (50%) had CCR and 9 patients (45%) had PR. The median duration of remission was 10.5 months in the bexarotene group and 4 months in the clobetasol propionate group. The remission period was statistically significantly longer in the bexarotene group (p = 0.032). Irritation symptoms were statistically significantly more common in the bexarotene group (p = 0.001).Study limitations: The limitation of the study was its retrospective design.Conclusion: Both topical bexarotene and topical clobetasol propionate were found to be effective in MF. Irritation symptoms were more common with topical bexarotene. Moreover, the remission period with topical bexarotene was significantly longer.","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anais brasileiros de dermatologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.abd.2024.04.011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There are few studies in the literature comparing the effectiveness of topical treatments in early-stage mycosis fungoides (MF).

Objectives: It was aimed to evaluate the clinical efficacy, side effects and topical treatment compliance with bexarotene or clobetasol propionate in early-stage MF.

Methods: A total of 40 patients with stage IA-IB MF were enrolled in the study. Twenty patients were treated with 1% bexarotene gel and 20 patients were treated with 0.05% clobetasol propionate ointment.

Results: In the bexarotene group, 11 patients (55%) had complete clinical response (CCR) and 5 patients (25%) had partial response (PR) while in the clobetasol propionate group, 10 patients (50%) had CCR and 9 patients (45%) had PR. The median duration of remission was 10.5 months in the bexarotene group and 4 months in the clobetasol propionate group. The remission period was statistically significantly longer in the bexarotene group (p = 0.032). Irritation symptoms were statistically significantly more common in the bexarotene group (p = 0.001).

Study limitations: The limitation of the study was its retrospective design.

Conclusion: Both topical bexarotene and topical clobetasol propionate were found to be effective in MF. Irritation symptoms were more common with topical bexarotene. Moreover, the remission period with topical bexarotene was significantly longer.

查看原文本刊更多论文

丙酸氯倍他索与贝沙罗汀治疗早期蕈样真菌病疗效比较。

背景：文献中很少有比较早期真菌样真菌病（MF）局部治疗效果的研究。目的：评价贝沙罗汀或丙酸氯倍他索治疗早期MF的临床疗效、毒副作用及局部治疗依从性。方法：共纳入40例IA-IB期MF患者。20例患者采用1%贝沙罗汀凝胶治疗，20例采用0.05%丙酸氯倍他索软膏治疗。结果：贝沙罗汀组完全缓解（CCR） 11例（55%），部分缓解（PR） 5例（25%）；丙酸氯倍他索尔组完全缓解（CCR） 10例（50%），部分缓解（PR） 9例（45%）。贝沙罗汀组缓解的中位时间为10.5个月，丙酸氯倍他索尔组缓解的中位时间为4个月。贝沙罗汀组缓解期明显长于贝沙罗汀组（p = 0.032）。贝沙罗汀组的刺激症状在统计学上更为常见（p = 0.001）。研究局限性：本研究的局限性在于其回顾性设计。结论：外用贝沙罗汀和丙酸氯倍他索治疗MF均有效。局部使用贝沙罗汀时，刺激症状更为常见。此外，局部使用贝沙罗汀的缓解期明显更长。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anais brasileiros de dermatologia DERMATOLOGY-

CiteScore

2.40

自引率

0.00%

发文量

184

审稿时长

32 days

期刊介绍： The journal is published bimonthly and is devoted to the dissemination of original, unpublished technical-scientific study, resulting from research or reviews of dermatological topics and related matters. Exchanges with other publications may be accepted.